MedTrace Logo

Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal

NCT00905333 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2010-12-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetic interaction of test formulations of candesartan and felodipine in a combination package comparing with the fasting intake of commercial formulations of both Atacand ® and Splendil®

Conditions

  • Healthy

Interventions

DRUG

Candesartan (test)

16 mg oral tablet, single dose

DRUG

Felodipine (test)

5 mg oral extended release tablet, single dose

DRUG

Candesartan Cilexetil

16 mg oral tablet, single dose

DRUG

Felodipine

5 mg oral extended release tablet, single dose

Sponsors & Collaborators

  • Scentryphar Clinical Research

    collaborator OTHER

  • Cori Analyticals

    collaborator UNKNOWN

  • Clínica São Lucas, Hospital Sírio Libanês de Itatiba S/C

    collaborator UNKNOWN

  • LabClin Laboratório Clínico

    collaborator UNKNOWN

  • Laboratório de Patologia Clínica Dr. Franceschi Ltda.

    collaborator UNKNOWN

  • Faculty of Pharmaceutical Sciences of Ribeirão Preto - Bioequivalence Center

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Eduardo Abib Junior, MD · Scentryphar Clinical Research

  • Moises L. P Vanuncci, MD · Scentryphar Clinical Research

Study Design

Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00905333 on ClinicalTrials.gov